Human malignant mesothelioma cell growth: Activation of janus kinase 2 and signal transducer and activator of transcription 1α for inhibition by interferon-γ

Cancer Research

Volumn 58, Issue 4, 1998, Pages 840-847

  Buard, Annie ^a   Vivo, Claire ^a   Monnet, Isabelle ^b   Boutin, Christian ^c   Pilatte, Yannick ^a   Jaurand, Marie Claude ^a  

^a FACULTÉ DE MÉDECINE   (France)

^b CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CYTOKINE; PROTEIN TYROSINE KINASE; RECOMBINANT GAMMA INTERFERON; TRANSCRIPTION FACTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL GROWTH; CLINICAL ARTICLE; ENZYME ACTIVATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MESOTHELIOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

CELL DIVISION; DNA-BINDING PROTEINS; ENZYME ACTIVATION; HUMANS; INTERFERON-GAMMA, RECOMBINANT; JANUS KINASE 2; MESOTHELIOMA; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0032520059     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Antman, K. H. Natural history and epidemiology of malignant mesothelioma. Chest, 103 (Suppl.): 373S-376S, 1993.
2. Boutin, C., Rey, F., Gouvernet, J., Viallat, J. R., Astoul, P., and Ledoray, V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Cancer (Phila.), 72: 394-404, 1993.
3. Boutin, C., Viallat, J. R., Van Zandwijk, N., Douillard, J-Y., Paillard, J-C., Guerin, J-C., Mignot, P., Migueres, J., Varlet, F., Jehan, A., Delepoulle, E., and Brandely, M. Activity of intrapleural recombinant γ-interferon in malignant mesothelioma. Cancer (Phila.), 67: 2033-2037, 1991.
4. Boutin, C., Nussbaum, E., Monnet, I., Bignon, J., Vanderschueren, R., Guerin, J-C., Menard, O., Mignot, P., Dabouis, G., and Douillard, J-Y. Intrapleural treatment with recombinant γ-interferon in early stage malignant pleural mesothelioma. Cancer (Phila.), 74: 2460-2467, 1994.
5. Christmas, T. I., Manning, L. S., Garlepp, M. J., Musk, A. W., and Robinson, B. W. S. Effect of inlerferon-α2a on malignant mesothelioma. J. Interferon Res., 13: 9-12, 1993.
6. Astoul, P., Viallat, J. R., Laurent, J. C., Brandely, M., and Boutin, C. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest, 103: 209-213, 1993.
7. Farrar, M. A., and Schreiber, R. D. The molecular cell biology of interferon-γ and its receptor. Annu. Rev. Immunol., 11: 571-611, 1993.
8. Billiau, A. Interferon-γ: biology and role in pathogenesis. Adv. Immunol., 62: 61-130, 1996.
9. Kimchi, A. Cytokine triggered molecular pathways that control cell cycle arrest. J. Cell. Biochem., 50: 1-9, 1992.
10. Saunders, N. A., Smith, R. J., and Jetten. A. M. Differential responsiveness of human bronchial epithelial cells, lung carcinoma cells, and bronchial fibroblasts to interferon-γ in vitro. Am. J. Respir. Cell Mol. Biol., 11: 147-152, 1994.
11. 1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma. Cell Growth Differ., 7: 289-300, 1996.
12. Marcel, T., and Grausz, J. D. The TMC worldwide gene therapy enrollment report (June 1996). Hum. Gene Ther., 7: 2025-2046, 1996.
13. Ross, G., Erickson, R., Knorr, D., Motulsky, A. G., Parkman, R., Samulski, J., Straus, S. E., and Smith, B. R. Gene therapy in the United States: a five-year status report. Hum. Gene Ther., 7: 1781-1790, 1996.
14. Monti, G., Jaurand, M-C., Monnet, I., Chrétien, P., Saint-Etienne, L., Zeng, L., Portier, A., Devillier, P., Galanaud, P., Bignon, J., and Emilie, E. Intrapleural production of interleukin 6 during mesothelioma, and its modulation by γ-interferon treatment. Cancer Res., 54: 4419-4423, 1994.
15. Zeng, L., Buard, A., Monnet, I., Boutin, C., Fleury, J., Saint-Etienne, L., Brochard, P., Bignon, J., and Jaurand, M-C. In vitro effects of recombinant human interferon γ on human mesothelial cell lines. Int. J. Cancer, 55: 515-520, 1993.
16. Phan-Bich, L., Buard, A., Petit, J-F., Zeng, L., Tenu, J-P., Chrétien, P., Monnet, I., Boutin, C., Bignon, J., Lemaire, G., and Jaurand, M-C. Differential responsiveness of human and rat mesothelioma cell lines to recombinant interferon-γ. Am. J. Respir. Cell Mol. Biol., 16: 178-186, 1997.
17. Müller, M., Briscoe, J., Laxton, C., Guschin, D., Ziemiecki, A., Silvennoinen, O., Harpur, A. G., Barbieri, G., Witthuhn, B. A., Schindler, C., Pellegrini, S., Wilks, A. F., Ihle, J. N., Stark, G. R., and Kerr, I. M. The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction. Nature (Lond.), 366: 129-135, 1993.
18. Watling, D., Guschin, D., Müller, M., Silvennoinen, O., Witthuhn, B. A., Quelle, F. W., Rogers, N. C., Schindler, C., Stark, G. R., Ihle, J. N., and Kerr, I. M. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-γ signal transduction pathway. Nature (Lond.), 366: 166-170, 1993.
19. Schindler, C., and Darnell, J. E. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem., 64: 621-651, 1995.
20. Durbin, J. E., Hackenmiller, R., Simon, M. C., and Levy, D. E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell, 84: 443-450, 1996.
21. Meraz, M. A., White, J. M., Sheehan, K. C. F., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., Carver-Moore, K., DuBois, R. N., Clark, R., Aguet, M., and Schreiber, R. D. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell, 84: 431-442, 1996.
22. Müller, M., Laxton, C., Briscoe, J., Schindler, C., Improta, T., Darnell, J. E., Stark, G. R., and Kerr, I. M. Complementation of a mutant cell line: central role of the p91 kDa polypeptide of ISGF3 in the interferon-α and -γ signal transduction pathways. EMBO J., 12: 4221-4228, 1993.
23. Briscoe, J., Rogers, N. C., Witthuhn, B. A., Watling, D., Harpur, A. G., Wilks, A. F., Stark, G. R., Ihle, J. N., and Kerr, I. M. Kinase-negative mutants of JAK1 can sustain Interferon-γ-inducible gene expression but not an antiviral state. EMBO J., 15: 799-809, 1996.
24. WAF1/CIP1 mediated by STAT1. Science (Washington DC), 272: 719-722, 1996.
25. Zeng, L., Fleury-Feith, J., Monnet, I., Boutin, C., Bignon, J., and Jaurand, M-C. Immunocytochemical characterization of cell lines from human malignant mesothelioma. Hum. Pathol., 25: 227-234, 1994.
26. Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., and Darnell, J. E. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon α and Interferon γ. Proc. Natl. Acad. Sci. USA, 93: 7673-7678, 1996.
27. Harada, H., Kitagawa, M., Tanaka, N., Yamamoto, H., Harada, K., Ishihara, M., and Taniguchi, T. Anti-oncogenic and oncogenic potential of interferon regulatory factors-1 and -2. Science (Washington DC), 259: 971-974, 1993.
28. Kirchhoff, S., Schaper, F., and Hauser, H. Interferon regulatory factor 1 (IRF-1) mediates cell growth inhibition by transactivation of downstream target genes. Nucleic Acids Res., 21: 2881-2889, 1993.
29. Pine, R., Canova, A., and Schindler, C. Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by IFNα and IFN-γ, and is likely to autoregulate the p91 gene. EMBO J., 13: 158-167, 1994.
30. Bach, E. A., Tanner, J. W., Marsters, S., Ashkenazi, A., Aguet, M., Shaw, A. S., and Schreiber, R. D. Ligand-induced assembly and activation of the γ interferon receptor in intact cells. Mol. Cell. Biol., 16: 3214-3221, 1996.
31. Kotenko, S. V., Izotova, L. S., Pollack, B. P., Mariano, T. M., Donnelly, R. J., Muthukumaran, G., Cook, J. R., Garotta, G., Silvennoinen, O., Ihle, J. N., and Pestka, S. Interaction between the components of the interferon γ receptor complex. J. Biol. Chem., 270: 20915-20921, 1995.
32. Han, Y., Leaman, D. W., Watling, D., Rogers, N. C., Groner, B., Kerr, I. M., Wood, W. I., and Stark, G. R. Participation of JAK and STAT proteins in growth hormoneinduced signaling. J. Biol. Chem., 271: 5947-5952, 1996.
33. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., Levitzki, A., and Roifman, C. M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (Lond.), 379: 645-648, 1996.
34. Eilers, A., Georgellis, D., Klose, B., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., and Decker, T. Differentiation-regulated serine phosphorylation of STAT1 promotes GAF activation in macrophages. Mol. Cell. Biol., 15: 3579-3586, 1995.
35. Wen, Z., Zhong, Z., and Damell, J. E. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell, 82: 241-250, 1995.
36. Zhang, X., Blenis, J., Li, H-C., Schindler, C., and Chen-Kiang, S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science (Washington DC), 267: 1990-1994, 1995.
37. Xu, X., Sun, Y-L., and Hoey, T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science (Washington DC), 273: 794-797, 1996.
38. Leaman, D. W., Leung, S., Li, X., and Stark, G. R. Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J., 10: 1578-1588, 1996.
39. Gerwin, B. Mesothelial carcinogenesis. Possible avenues of growth factor promotion. In: M-C. Jaurand and J. Bignon (eds.). The Mesothelial Cell and Mesothelioma, Vol. 78, pp. 223-243. New York: Marcel Dekker, Inc., 1994.
40. Fitzpatrick, D. R., Peroni, D. J., and Bielefeldt-Ohmann, H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am. J. Respir. Cell Mol. Biol., 12: 455-460, 1995.